FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis
- 4 January 2007
- journal article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 37 (2), 153-154
- https://doi.org/10.1111/j.1365-2362.2007.01757.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment conceptsEuropean Journal of Clinical Investigation, 2004
- The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementBlood, 2004
- CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyBlood, 2003
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001
- Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemiaMolecular Pathology, 2000
- Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.Proceedings of the National Academy of Sciences of the United States of America, 1995
- Classification and Diagnosis of Mastocytosis: Current StatusJournal of Investigative Dermatology, 1991
- Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disordersBritish Journal of Haematology, 1990
- Significance of systemic mast cell disease with associated hematologic disordersCancer, 1988